(Q31156315)

29 June 2017

1 reference

title

Mitomycin C in the treatment of gastrointestinal tumours: recent data and perspectives (English)

1 reference

29 June 2017

Ralf-Dieter Hofheinz

1

1 reference

29 June 2017

Ulrich Beyer

series ordinal

2

1 reference

29 June 2017

Salah-Eddin Al-Batran

series ordinal

3

1 reference

29 June 2017

Jörg Thomas Hartmann

series ordinal

4

1 reference

29 June 2017

publication date

10 April 2008

1 reference

29 June 2017

1 reference

29 June 2017

volume

31

1 reference

29 June 2017

issue

5

1 reference

29 June 2017

page(s)

271-281

1 reference

Mitomycin C: a clinical update

29 June 2017

cites work

1 reference

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

21 January 2018

1 reference

Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial

21 January 2018

1 reference

High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study

21 January 2018

1 reference

Infusional 5-fluorouracil and mitomycin C: an effective regimen in the treatment of advanced gastric cancer

21 January 2018

1 reference

Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study

21 January 2018

1 reference

Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study

21 January 2018

1 reference

Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer

21 January 2018

1 reference

Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).

21 January 2018

1 reference

Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen

21 January 2018

1 reference

Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer

21 January 2018

1 reference

Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience

21 January 2018

1 reference

Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial

21 January 2018

1 reference

Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma

21 January 2018

1 reference

A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer

21 January 2018

1 reference

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

21 January 2018

1 reference

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan

21 January 2018

1 reference

Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000122590

1 reference

29 June 2017

1 reference